https://scholars.lib.ntu.edu.tw/handle/123456789/495031
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | JIH-HSIANG LEE | en_US |
dc.contributor.author | Lin Y.-L. | en_US |
dc.contributor.author | Hsu W.-H. | en_US |
dc.contributor.author | Chen H.-Y. | en_US |
dc.contributor.author | YEUN-CHUNG CHANG | en_US |
dc.contributor.author | CHONG-JEN YU | en_US |
dc.contributor.author | JIN-YUAN SHIH | en_US |
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | KUAN-YU CHEN | en_US |
dc.contributor.author | CHAO-CHI HO | en_US |
dc.contributor.author | WEI-YU LIAO | en_US |
dc.contributor.author | PAN-CHYR YANG | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.creator | Lee J.-H;Lin Y.-L;Hsu W.-H;Chen H.-Y;Chang Y.-C;Yu C.-J;Shih J.-Y;Lin C.-C;Chen K.-Y;Ho C.-C;Laio W.-Y;Yang P.-C;Chih-Hsin Yang | - |
dc.date.accessioned | 2020-05-26T09:27:00Z | - |
dc.date.available | 2020-05-26T09:27:00Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906314041&doi=10.1097%2fJTO.0000000000000238&partnerID=40&md5=a2fcd63b468c22881b528addfc3493fc | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/495031 | - |
dc.description.abstract | INTRODUCTION: Germline Bcl-2-like protein 11 (BIM) deletion polymorphism in Asian is a poor predictive factor for treatment outcomes to tyrosine kinase inhibitors (TKIs) in malignancies. We explored the impact of BIM deletion polymorphism on treatment outcome of advanced non-small-cell lung cancer (NSCLC). METHODS: We prospectively collected tissue samples, blood, and clinical data from two cohorts of advanced NSCLC patients. BIM deletion polymorphism was correlated with overall survival (OS) and progression-free survival (PFS) to epidermal growth factor receptor (EGFR) TKIs and chemotherapy treatment. RESULTS: BIM deletion polymorphism was detected in blood of 16.2% (33 of 204) patients. The PFS to first-line EGFR-TKIs in 153 patients were 8.6 and 4.6 months for patients with wild-type BIM and BIM deletion polymorphism, respectively (p = 0.004). Among 120 patients who received chemotherapies, the PFS to chemotherapies were 5.6 and 3.5 months for patients with wild-type BIM and BIM deletion polymorphism, respectively (p = 0.050). The OS of all 204 patients was 24.8 and 16.8 months for patients with wild-type BIM and BIM deletion polymorphism, respectively (p = 0.005). Multivariate analyses suggested that BIM deletion polymorphism was an independent predictor for shorter PFS to EGFR-TKIs (hazard ratio [HR] 2.15, p = 0.002), PFS to chemotherapy (HR 2.40, p = 0.016), and OS (HR 1.65, p = 0.039). CONCLUSIONS: BIM deletion polymorphism predicts shorter PFS to EGFR-TKIs and OS in advanced NSCLC. Copyright ? 2014 by the International Association for the Study of Lung Cancer. | - |
dc.publisher | Lippincott Williams and Wilkins | - |
dc.relation.ispartof | Journal of Thoracic Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | BIM protein; epidermal growth factor receptor; gefitinib; protein bcl 2; protein tyrosine kinase inhibitor; apoptosis regulatory protein; Bcl-2-like protein 11; DNA; membrane protein; oncoprotein; adult; advanced cancer; article; blood; cancer chemotherapy; clinical trial (topic); DNA polymorphism; female; gene deletion; human; lung non small cell cancer; major clinical study; male; overall survival; predictive value; priority journal; progression free survival; prospective study; tissues; treatment outcome; wild type; disease free survival; epidemiology; follow up; gene deletion; genetic polymorphism; genetics; lung tumor; metabolism; middle aged; mortality; mutation; non small cell lung cancer; nucleotide sequence; polymerase chain reaction; prognosis; survival rate; Taiwan; trends; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Sequence Deletion; Survival Rate; Taiwan | - |
dc.title | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1097/JTO.0000000000000238 | - |
dc.identifier.pmid | 25057939 | - |
dc.identifier.scopus | 2-s2.0-84906314041 | - |
dc.relation.pages | 1385-1392 | - |
dc.relation.journalvolume | 9 | - |
dc.relation.journalissue | 9 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Medical Imaging-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | National Taiwan University Hospital Hsin-Chu Branch | - |
crisitem.author.dept | NTU BioMedical Park Hospital | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Medicine-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Biomedical Electronics and Bioinformatics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0002-8716-1602 | - |
crisitem.author.orcid | 0000-0001-9984-5713 | - |
crisitem.author.orcid | 0000-0001-5664-9392 | - |
crisitem.author.orcid | 0000-0002-2854-5067 | - |
crisitem.author.orcid | 0000-0002-5639-9773 | - |
crisitem.author.orcid | 0000-0002-8156-2413 | - |
crisitem.author.orcid | 0000-0001-6383-3470 | - |
crisitem.author.orcid | 0000-0001-6330-6048 | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital Hsin-Chu Branch | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。